Annovis Bio Misses Q1 Earnings Expectations

Biotech firm's stock falls after reporting wider-than-expected loss per share

Mar. 13, 2026 at 9:33pm

Got story updates? Submit your updates here. ›

Annovis Bio (NYSE:ANVS), a clinical-stage biotech company focused on neurodegenerative disorders, reported its first quarter financial results on Friday. The company posted a loss of $0.39 per share, missing the consensus estimate of a $0.31 loss per share by $0.08.

Why it matters

Annovis Bio's miss on earnings expectations could raise concerns among investors about the company's ability to effectively develop and commercialize its lead drug candidate, ANVS401, which is being evaluated for the treatment of Alzheimer's and Parkinson's diseases. The stock price drop following the earnings release indicates that the market is closely watching the company's financial performance and pipeline progress.

The details

In its Q1 report, Annovis Bio attributed the wider-than-expected loss to increased research and development expenses as it continues advancing ANVS401 through clinical trials. The company reported a net loss of $10.4 million for the quarter, compared to a $6.9 million loss in the same period a year earlier.

  • Annovis Bio reported its Q1 2026 financial results on Friday, March 13, 2026.

The players

Annovis Bio

A clinical-stage biotech company focused on developing treatments for neurodegenerative disorders, including Alzheimer's and Parkinson's diseases.

Got photos? Submit your photos here. ›

What’s next

Annovis Bio plans to provide an update on the development of ANVS401 and its other pipeline programs during its upcoming investor conference call.

The takeaway

Annovis Bio's Q1 earnings miss highlights the challenges biotech companies face in developing new drugs and meeting investor expectations. The company's ability to effectively manage its finances and advance its pipeline will be crucial in determining its long-term success.